Teijin Regenet joins ACGMP as founding member
- Signed an agreement on September 25, 2026 to join ACGMP as a founding member.
- ACGMP is a global alliance of CDMOs focused on cell and gene therapy (CGT) to provide technical and regional manufacturing support.
- The alliance will pursue joint promotion, client referrals, collaborative projects, and common tools for quality management and technology transfer.
- Teijin Regenet expects to strengthen its global development and manufacturing network and enhance support for CGT developers in Japan and overseas.
Transaction
Teijin Regenet entered an agreement on September 25, 2026 to join the Alliance of CGT Manufacturing Partners (ACGMP) as a founding member.
Industry context
R&D in cell and gene therapy (CGT) is expanding globally while manufacturing complexity and stricter quality and regulatory requirements increase demand for specialized CDMOs and multi-region manufacturing, quality and regulatory support.
ACGMP objectives
ACGMP brings together specialized CDMOs across countries and regions to give therapy developers access to partners with required technical expertise and regional infrastructure. The alliance plans joint promotional activities, client referrals, collaborative projects, and development of common tools for quality management and technology transfer, plus collaboration among member technical and quality teams.
Expected impact and strategy
By joining ACGMP, Teijin Regenet aims to strengthen its global development and manufacturing network and enhance support capabilities for CGT developers in Japan and overseas. The move aligns with the Teijin Group's mid-term strategy based on the "Suriawase × Kumiawase" concept to leverage internal and external technologies, expertise and networks to support commercialization and wider adoption of innovative CGT.
Source: Teijin